Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008

REDWOOD CITY, Calif., May 12 /PRNewswire/ -- Emphasys Medical Inc., today announced that one-year data from the VENT clinical trial of the company's Zephyr(R) Endobronchial Valve (EBV) will be presented at the International Conference of the American Thoracic Society (ATS) occurring May 16 to 21 in Toronto, Canada.

Sunday, May 18, 9:30-11:00 a.m. (ET), Metro Toronto Convention Centre, Room 801A

In the symposium, "Innovations in Emphysema Treatment: Lung Volume Reduction and Lung Volume Reduction Surgery," Zephyr related presentations include:

-- Frank Sciurba, M.D., University of Pittsburgh Medical Center, the
principal investigator of VENT, will present on the Durability of
Endobronchial Valve Effect on Lung Function at 6 and 12 Months.

-- Jonathan Goldin, M.D., Ph.D., University of California at Los Angeles,
the principal investigator of the VENT radiology core lab, will
present on Fissure Integrity As a Marker of Collateral Ventilation
Across Lung Lobes.

-- Jim Egan, M.D., Mater Misericordiae Hospital, Dublin, Ireland, will
present on the Treatment of Advanced Emphysema by Endoscopic Volume
Reduction.

-- John Travaline, M.D., Temple University, will present on the Efficacy
of Endobronchial Valves in the Treatment of Persistent Air Leaks.

Monday, May 19, 8:30 a.m., Metro Toronto Convention Centre, Room 715A

-- Charlie Strange, M.D., Medical University of South Carolina will
present on the relation of FEV1/FVC and Fissure Integrity in the VENT
Study.

Monday, May 19, 3:10 p.m., Metro Toronto Convention Centre, Hall G

-- Frank Sciurba, M.D., will present on Bronchoscopic Methods for
Palliation of Emphysema.

About the Zephyr Endobronchial Valve

The Zephyr EBV is a novel, minimally-invasive device intended to treat emphysema. The Zephyr EBV is designed to isolate diseased, overinflated portions of the lung and cause them to shrink thereby allowing healthier portions of the lung to function more normally.

The Zephyr EBV is CE marked and is commercially available in Europe and other international markets, including Australia, New Zealand, Hong Kong and Singapore. The Zephyr EBV is limited to investigational use in the United States. The company's Premarket Approval Application is currently under review by the U.S. Food and Drug Administration.

About Emphasys Medical

Emphasys Medical (http://www.emphasysmedical.com/) is a medical technology company focused on developing and commercializing therapeutic devices for the treatment of patients with emphysema and other debilitating breathing disorders. Based in Redwood City, California, Emphasys Medical was incubated at The Foundry.

First Call Analyst:
FCMN Contact:

Source: Emphasys Medical Inc.

CONTACT: Greg Bakan of Emphasys Medical, +1-650-364-0400,
info@emphasysmedical.com

Web site: http://www.emphasysmedical.com/

2008-05-12 18:30:58 0359425 PRNEWSWIRE